In its clinical trial to treat prostate cancer, Madison Vaccines Incorporated (MVI) announced today it has begun dosing 20 patients. According to a release, MVI is exploring the use of its gene…

Madison Vaccines Incorporated’s clinical trial for metastatic prostate cancer is expanding to the University of Washington, its third site, the company announced recently. According to a release, MVI-118 is being explored for…

Madison Vaccines Incorporated (MVI) announced today it will present data at the Society for Immunotherapy of Cancer’s Annual Meeting on Nov. 11 in National Harbor, Md., that has “promise” to stimulate an immune…

Madison Vaccines Incorporated (MVI) announced this week it raised $8 million in a Series A financing round led by Venture Investors, LLC. The Madison-based biopharmaceutical company seeks to advance research and clinical testing…